USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy

Gemcitabine is the cornerstone of pancreatic cancer treatment. Although effective in most patients, development of tumor resistance to gemcitabine can critically limit its efficacy. The mechanisms responsible for this phenomenon remain elusive, but evidence suggests that ubiquitin-specific peptidases (USPs) may be key regulators in cancer chemo-resistance. The present study aimed to investigate the role of USP9X in gemcitabine resistance using in vitro pancreatic cell lines and a mouse xenograft model.

Source: Cancer Letters - August 14, 2018 Category: Cancer & Oncology Authors: Tao Ma, Wei Chen, Xiao Zhi, Hao Liu, Yue Zhou, Brayant Wei Chen, Liqiang Hu, Jian Shen, Xiaoxiao Zheng, Shufen Zhang, Tingbo Liang Tags: Original Articles Source Type: research